New approaches to primary brain tumor treatment.

New approaches to primary brain tumor treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

New approaches to primary brain tumor treatment. Abstract Text:

Sith Sathornsumetee,Jeremy N Rich,

Primary brain tumors represent over 100 different tumor types with widely divergent biologies and clinical outcomes, but these neoplasms frequently pose similar challenges to neuro-oncologists. Malignant gliomas are the most common type of primary intrinsic brain tumor in adults and remain extremely lethal. Current standard-of-care therapies for these cancers include surgery, radiation and palliative cytotoxics, which have significant side-effects and limited efficacy. Advances in our understanding of the molecular underpinnings of cancer have led to targeted molecular therapies that may permit improvement in therapeutic efficacy and reduced toxicity; these therapies, however, still face many challenges. Signal transduction pathways that are inappropriately regulated in brain cancers include growth factors and their receptors (e.g. epidermal growth factor receptor, vascular endothelial growth factor receptor and platelet-derived growth factor receptor), which regulate cellular interactions with the microenvironment and intracellular oncogenic pathways. Low-molecular-weight inhibitors have been developed to target many kinases and may have advantages in terms of delivery. Monoclonal antibodies may have greater specificity, but face delivery restrictions. Preferential tumor delivery of chemotherapies, conjugated toxins and radioisotopes has been achieved through convection-enhanced delivery, intratumoral implants and intra-arterial infusion. Despite these advances, few molecularly targeted therapies have demonstrated significant antineoplastic activity for a broad range of patients, possibly due to tumor and patient heterogeneity. Improved functional neuropathology and imaging may permit identification of patient subgroups for which clinical responses may be enriched. It is probable, however, that targeted therapies will be most effective in combination either with one another or with cytotoxic therapies. In this study, we review the current state of new therapies for malignant gliomas.

New approaches to primary brain tumor treatment. Publishing Authors By Initials

S Sathornsumetee,JN Rich,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

New approaches to primary brain tumor treatment. Journal Published:

PUBLICATION TYPE: Review

Journal: Anti-cancer drugs

VOLUME: 17

Page Numbers: 1003-16

Journal Abbreviation:

ISSN: 0959-4973

DAY: 3

MONTH: Oct

YEAR: 2006

New approaches to primary brain tumor treatment. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9100823

New approaches to primary brain tumor treatment. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: New approaches to primary brain tumor treatment. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for New approaches to primary brain tumor treatment.

AFFILIATION: Departments of Medicine, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Anticancer Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

New approaches to primary brain tumor treatment Related Publications

• ... and what they've got to share.
• A Chronic Pain Patient's Perspective on Opioid Tolerance.
• A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
• AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
• An Alu-mediated rearrangement causing a 3.2kb deletion and a novel two base pair deletion in AAAS gene as the cause of triple A syndrome.
• Assessing adolescents with insulin-dependent diabetes mellitus: a multiple perspective pilot study using visual illness narratives and interviews.
• Cancer symptom complexes related to alterations in molecular circadian axis signaling.
• Cardiac surgery in nonagenarians.
• Database size and power to detect safety signals in pharmacovigilance.
• Demographic, geographic, and temporal patterns of ambulance runs for suspected opiate overdose in Rhode Island, 1997-20021.
• Dysembryoplastic neuroepithelial tumor and oligodendroglioma: the diagnostic value of magnetic resonance spectroscopy. Case report and review of the literature.
• Dysregulation of sodium channel gating in critical illness myopathy.
• Eat less, live longer? New insights into the role of caloric restriction in the brain.
• Epidemiology, pathophysiology, and prognosis of heart failure in the elderly.
• Five years' experience with long saphenous catheterisation for chronic venous access.
• Genetic contributions to type 2 diabetes: recent insights.
• Gonzales versus Oregon:the Oregon Death with Dignity Act Meets the Controlled Substances Act.
• Heroin in the corrections system: introduction.
• Ketosis and nitrogen excretion in undernourished surgical patients.
• Limited spending: an analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners.
• Linkage to methadone treatment from acute opiate detoxification treatment.
• Molecularly targeted therapy for malignant glioma.
• New approaches to primary brain tumor treatment.
• Opiate replacement therapy at time of release from incarceration: Project MOD, a pilot program.
• Plagiarism in an article: is there any evidence?
• The cancer stem cell: a new therapeutic paradigm?
• The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.
• Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside.
• Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
• Willingness to receive an HIV vaccine among incarcerated persons.